Compare iShares MSCI Canada (TSX) (EWC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs TransMedics Group Inc — how do they compare? iShares MSCI Canada (TSX) trades at $59.03 (market cap $6.99B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: iShares MSCI Canada (TSX) is far larger — about 2.6× TransMedics Group Inc's market cap, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 56 Days and TransMedics Group Inc for 24 Days on average.
| EWC | TMDX | |
|---|---|---|
Market Cap | $6.99B | $2.74B |
Volume | 1,625,847 | 949,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $150.42 |
52-Week Low | $49.72 | $61.99 |
Typical Hold Time | 56 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $58.32, up 0.66% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Key support is at $58, with resistance at $59. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights trade tensions with the U.S. and Canada's pursuit of EU associate membership, creating uncertainty.
The outlook is clouded by geopolitical risks and lack of financial data. Upside depends on resolving trade disputes, but downside risks from U.S. tariff threats and economic softening in Canada persist. Investors need updated earnings and valuation metrics to assess true potential amid volatile conditions.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
